Business Context and Reporting Period
Company: Advanced Biomed Inc. (Nasdaq: ADVB)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2025
Business Overview: Advanced Biomed is a holding company incorporated in Nevada, operating primarily through subsidiaries in Taiwan and China. The company focuses on developing microfluidic technology platforms for early cancer detection, specifically targeting circulating tumor cells (CTCs). Key products include the A+Pre, AC-1000, A+CellScan, and A+SCDrop devices, along with the A+LCGuard lung cancer screening kit. As of the report date, the company has no revenue-generating products and is in the pre-commercialization stage, awaiting regulatory approvals from the National Medical Products Administration (NMPA) in China.
Key Financial Metrics
| Metric | Year Ended June 30, 2025 | Year Ended June 30, 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(3,258,969) | $(2,782,278) |
| Operating Expenses | $(3,021,036) | $(2,541,572) |
| Research & Development Expenses | $(909,771) | $(880,193) |
| General & Administrative Expenses | $(2,111,265) | $(1,661,379) |
| Cash and Cash Equivalents (End of Period) | $2,903,915 | $2,607,973 |
| Net Cash Used in Operating Activities | $(5,825,055) | $(2,126,340) |
| Working Capital | $3,143,443 | $318,650 |
Note: The company reported no revenue for either period. Margins and profit metrics are not applicable due to zero revenue.
Material Changes vs. Prior Period
- Increased Net Loss: Net loss increased by approximately 17% (from $2.78 million to $3.26 million) driven primarily by higher General and Administrative (G&A) expenses.
- G&A Expense Surge: G&A expenses rose by 27% ($449,886 increase), largely due to a 187% increase in legal and professional fees ($653,489 increase) and a 196% increase in office supplies and upkeep expenses, partially offset by a 34% decrease in staff costs.
- Capital Raising: The company completed its Initial Public Offering (IPO) in March 2025, issuing 1,640,000 shares at $4.00 per share, generating gross proceeds of $6.56 million. Net proceeds were approximately $5.49 million.
- Financing Agreement: Entered into an Equity Line of Credit (ELOC) Agreement on June 6, 2025, allowing for the potential sale of up to $25 million of common stock to Helena Global Investment Opportunities I Ltd.
- Working Capital Improvement: Working capital surplus improved significantly from $318,650 in 2024 to $3,143,443 in 2025, bolstered by IPO proceeds and related party debt waivers totaling $2.82 million.
Guidance, Outlook, and Risks
Outlook and Guidance: The company expects to remain in a state of continuous loss for the next two to three years. It does not anticipate generating revenue until clinical development is completed, regulatory filings are submitted, and approvals are received. Management believes existing cash ($2.9 million) is sufficient to fund operations for approximately 12 months from the date of the report. Clinical research for the A+LCGuard lung cancer screening kit is planned to begin in November 2025, with large-scale clinical trials anticipated to follow.
Material Risks and Contingencies:
- Going Concern: The independent auditor has issued an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows.
- Regulatory Delays: Commercialization is entirely dependent on NMPA approvals. Delays in clinical trials or regulatory reviews could significantly postpone product launches.
- Nasdaq Compliance: The company received a deficiency notice from Nasdaq on July 18, 2025, for failing to meet the $1.00 minimum bid price requirement. It has a 180-day compliance period (until January 14, 2026) to regain compliance or face potential delisting.
- Internal Controls: Management concluded that internal control over financial reporting was ineffective as of June 30, 2025, citing a lack of sufficient finance personnel and proper approval mechanisms.
- Geopolitical Risks: Operations are concentrated in Taiwan and China, exposing the company to geopolitical tensions, foreign exchange controls, and regulatory changes in those jurisdictions.
Key Facts for Investor Verification
- Revenue Status: Verify that the company has zero revenue and no products currently approved for commercial sale.
- Liquidity Runway: Confirm the sufficiency of the $2.9 million cash balance against the projected burn rate, given the "substantial doubt" going concern warning.
- Nasdaq Listing Status: Monitor the company's progress in regaining compliance with the Nasdaq minimum bid price requirement by January 14, 2026.
- Regulatory Milestones: Track the timeline for the A+LCGuard clinical research (planned start: November 2025) and subsequent NMPA registration approvals.
- Related Party Transactions: Review the significant reliance on related party loans and debt waivers (e.g., $2.82 million waived in 2024) to sustain operations.
- Internal Control Remediation: Assess the progress of management's plan to remediate material weaknesses in internal controls over financial reporting.